# US 8,278,413 B2 · Cell-permeable peptide inhibitors of the JNK signal transduction pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,413 B2
- Document ID: US8278413B2
- Status: Granted
- Kind: B2
- Application number: 13/222,115
- Filed: 2011-08-31
- Published: 2012-06-07
- Granted: 2012-10-02
- Earliest claimed: 1999-10-12
- Assignees: Xigen SA
- Inventors: Christophe Bonny
- Web page: https://patentgrep.com/patent/US8278413B2

## CPC

- C07K 14/4743: {Insulin-like growth factor binding protein}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressed cells.

## Claims

### Claim 1

A chimeric peptide capable of inhibiting the activation of at least one c-jun amino terminal kinase (JNK) signaling pathway, said chimeric peptide being 35 amino acids or less in length, comprising a first domain and a second domain linked by a covalent bond at either the N-terminal or the C-terminal end of the first domain, wherein the first domain comprises the amino acid sequence of SEQ ID NO: 8, and the second domain comprises a JNK inhibitor sequence selected from the group consisting of
a) a peptide with the amino acid sequence of SEQ ID NO:3 and
b) a peptide having at least 80% sequence identity to SEQ ID NO:3,
wherein the JNK inhibitor sequence is capable of inhibiting the activation of at least one JNK signaling pathway.

### Claim 2 (depends on 1)

The chimeric peptide of claim 1, wherein the first domain augments cellular uptake of the peptide.

### Claim 3 (depends on 1)

The chimeric peptide of claim 1, wherein the first domain directs nuclear localization of the peptide.

### Claim 4 (depends on 1)

The chimeric peptide of claim 1, wherein the JNK inhibitor sequence binds c-Jun amino terminal kinase (JNK).

### Claim 5 (depends on 1)

The chimeric peptide of claim 1, wherein the JNK signaling pathway comprises at least one transcription factor selected from the group consisting of c-Jun, ATF2, and Elk 1.

### Claim 6

A peptide consisting of the amino acid sequence of SEQ ID NO:3.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising the chimeric peptide of any of claims 1-5 and a pharmaceutically acceptable carrier.
